DE602004029500D1 - Verfahren zum schutz vor strahlung mit flagellin - Google Patents
Verfahren zum schutz vor strahlung mit flagellinInfo
- Publication number
- DE602004029500D1 DE602004029500D1 DE602004029500T DE602004029500T DE602004029500D1 DE 602004029500 D1 DE602004029500 D1 DE 602004029500D1 DE 602004029500 T DE602004029500 T DE 602004029500T DE 602004029500 T DE602004029500 T DE 602004029500T DE 602004029500 D1 DE602004029500 D1 DE 602004029500D1
- Authority
- DE
- Germany
- Prior art keywords
- flagellin
- protection against
- against radiation
- modulators
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010040721 Flagellin Proteins 0.000 title 1
- 230000005855 radiation Effects 0.000 title 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 2
- 108010057466 NF-kappa B Proteins 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4748—Details p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52649603P | 2003-12-02 | 2003-12-02 | |
US52646003P | 2003-12-02 | 2003-12-02 | |
US52646103P | 2003-12-02 | 2003-12-02 | |
US52666603P | 2003-12-02 | 2003-12-02 | |
PCT/US2004/040753 WO2005056042A2 (en) | 2003-12-02 | 2004-12-02 | Methods of protecting against radiation using flagellin |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004029500D1 true DE602004029500D1 (de) | 2010-11-18 |
Family
ID=34682348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004029500T Active DE602004029500D1 (de) | 2003-12-02 | 2004-12-02 | Verfahren zum schutz vor strahlung mit flagellin |
Country Status (19)
Country | Link |
---|---|
US (2) | US11235028B2 (de) |
EP (1) | EP1706133B1 (de) |
JP (1) | JP4750716B2 (de) |
KR (1) | KR101287905B1 (de) |
CN (1) | CN1913915B (de) |
AT (1) | ATE483467T1 (de) |
AU (1) | AU2004296828B2 (de) |
CA (1) | CA2547869C (de) |
DE (1) | DE602004029500D1 (de) |
DK (1) | DK1706133T3 (de) |
EA (1) | EA010291B1 (de) |
HK (1) | HK1102492A1 (de) |
IL (1) | IL175974A (de) |
PL (1) | PL1706133T3 (de) |
PT (1) | PT1706133E (de) |
SG (2) | SG148215A1 (de) |
SI (1) | SI1706133T1 (de) |
UA (1) | UA83272C2 (de) |
WO (3) | WO2005056055A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580321B2 (en) * | 2003-12-02 | 2013-11-12 | The Cleveland Clinic Foundation | Method for reducing the effects of chemotherapy using flagellin related polypeptides |
US8007812B2 (en) | 2004-12-22 | 2011-08-30 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
BRPI0611586A2 (pt) | 2005-06-13 | 2010-09-21 | Cleveland Biolabs Inc | métodos de proteção contra apoptose mediante uso de lipopeptìdeos |
CN101854802B (zh) | 2007-09-10 | 2014-12-03 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
ES2412237T3 (es) | 2008-08-01 | 2013-07-10 | Cleveland Biolabs, Inc. | Métodos para tratar lesiones por reperfusión |
KR101254244B1 (ko) * | 2010-11-01 | 2013-04-12 | 한국원자력의학원 | TGF-β1을 유효성분으로 함유하는 방사선 피폭 또는 조사에 의한 세포손상의 예방 또는 치료용 조성물 |
KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
CN102965386A (zh) * | 2011-09-02 | 2013-03-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法 |
CA2908380A1 (en) | 2013-04-09 | 2014-10-16 | Boston Biomedical, Inc. | Methods for treating cancer |
KR20150085146A (ko) * | 2014-01-13 | 2015-07-23 | 한국원자력의학원 | 소포체 스트레스 저해제를 포함하는 방사선 방호용 조성물 |
JP6940916B2 (ja) | 2014-07-30 | 2021-09-29 | ゲノム プロテクション,インコーポレイテッド | フラジェリン組成物および使用 |
WO2016109002A2 (en) | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
KR101634380B1 (ko) | 2015-06-23 | 2016-06-28 | 한국생산기술연구원 | Tlr5 아고니스트 단백질의 생산방법 |
SG11201804894XA (en) * | 2015-12-16 | 2018-07-30 | Hoffmann La Roche | Improved recombinant production method |
CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
SG11202010485VA (en) * | 2018-04-24 | 2020-11-27 | Genome Protection Inc | Methods for improving frailty and aging |
KR102524577B1 (ko) * | 2019-04-22 | 2023-04-21 | 전남대학교산학협력단 | 플라젤린 융합 단백질 및 이의 용도 |
KR20220052300A (ko) * | 2020-10-20 | 2022-04-27 | 전남대학교산학협력단 | 플라젤린 융합 단백질 및 이의 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399494A (en) | 1983-03-04 | 1995-03-21 | The University Of Maryland System | Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom |
US6130082A (en) * | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
US20020009747A1 (en) * | 1997-08-25 | 2002-01-24 | Freda Diane Miller | Methods and reagents for identifying modulators of neuronal apoptosis |
US7300749B2 (en) * | 2000-02-17 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
AU2002216500A1 (en) * | 2000-11-28 | 2002-06-11 | Genesis Research And Development Corporation Limited | Methods for modulating apoptotic cell death |
CA2462638A1 (en) * | 2001-10-02 | 2003-04-10 | University Of Chicago | Methods and compositions for modulating apoptosis |
US7078165B2 (en) * | 2003-03-27 | 2006-07-18 | Institut Pasteur | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
US7638485B2 (en) | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
US8007812B2 (en) | 2004-12-22 | 2011-08-30 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
-
2004
- 2004-12-02 UA UAA200607304A patent/UA83272C2/uk unknown
- 2004-12-02 SG SG200809013-6A patent/SG148215A1/en unknown
- 2004-12-02 KR KR1020067010934A patent/KR101287905B1/ko active IP Right Grant
- 2004-12-02 PL PL04813124T patent/PL1706133T3/pl unknown
- 2004-12-02 WO PCT/US2004/040750 patent/WO2005056055A2/en active Application Filing
- 2004-12-02 PT PT04813124T patent/PT1706133E/pt unknown
- 2004-12-02 WO PCT/US2004/040753 patent/WO2005056042A2/en active Application Filing
- 2004-12-02 EP EP04813124A patent/EP1706133B1/de active Active
- 2004-12-02 EA EA200601079A patent/EA010291B1/ru not_active IP Right Cessation
- 2004-12-02 JP JP2006542849A patent/JP4750716B2/ja not_active Expired - Fee Related
- 2004-12-02 CN CN2004800412595A patent/CN1913915B/zh active Active
- 2004-12-02 AU AU2004296828A patent/AU2004296828B2/en not_active Ceased
- 2004-12-02 WO PCT/US2004/040579 patent/WO2005057218A2/en active Application Filing
- 2004-12-02 DE DE602004029500T patent/DE602004029500D1/de active Active
- 2004-12-02 SG SG2011087681A patent/SG176524A1/en unknown
- 2004-12-02 CA CA2547869A patent/CA2547869C/en active Active
- 2004-12-02 SI SI200431577T patent/SI1706133T1/sl unknown
- 2004-12-02 DK DK04813124.7T patent/DK1706133T3/da active
- 2004-12-02 AT AT04813124T patent/ATE483467T1/de active
-
2006
- 2006-05-28 IL IL175974A patent/IL175974A/en active IP Right Grant
-
2007
- 2007-07-25 HK HK07108097.8A patent/HK1102492A1/xx not_active IP Right Cessation
-
2019
- 2019-07-31 US US16/527,770 patent/US11235028B2/en active Active
-
2021
- 2021-12-21 US US17/557,438 patent/US20220105155A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1102492A1 (en) | Methods of protecting against radiation using flagellin | |
NO20054988D0 (no) | Preparater og metoder for behandling av cancer | |
DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
ATE376835T1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
AU2209800A (en) | Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia | |
MXPA05008406A (es) | Compuestos de amida tri(ciclo)-sustituida. | |
ATE389649T1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
WO2009038720A3 (en) | Method and apparatus for applying light therapy | |
CY1108401T1 (el) | Παραγωγα πυρρολοϊμιδαζολης, η παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιεχουν και η χρηση τους ως νοοτροπικων παραγοντων | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
AR059945A1 (es) | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig | |
DE69813839D1 (de) | Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz | |
WO2021203103A3 (en) | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment | |
ATE375795T1 (de) | Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs | |
DE60037813D1 (de) | Antworten auf hypoxia modifizieren | |
MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. | |
ATE374025T1 (de) | Verbindungen zur beseitigung und/oder linderung der anhedonie | |
DK1152760T3 (da) | Anvendelse af 4-aminopyridin til behandling af perifere neuropatier | |
WO2005034868A8 (en) | Methods for treating igf1r-inhibitor induced hyperglycemia | |
WO2005056054A3 (en) | METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB | |
ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen |